



G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019

September 3, 2019

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses will present a company overview at the H.C. Wainwright Annual Global Investment Conference. The presentation will take place on Monday, September 9, 2019 at 9:35 a.m. at the Lotte New York Palace Hotel in New York, NY.

To access the live webcast presentation, please visit the [Events & Presentations page](#) within the Investors section of the [G1 website](#). The webcast will be archived on the same page for 90 days following the event.

About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. [Trilaciclib](#) is a first-in-class myelopreservation agent designed to improve outcomes for patients being treated with chemotherapy. [Lerociclib](#) is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies. [G1T48](#) is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:

Jeff Macdonald
Head of Investor Relations / Public Relations
919-907-1944
jmacdonald@g1therapeutics.com



Source: G1 Therapeutics